Hide

FocusBar

FeedbackFeedback
Subscribe to Premium Member
7.92 (1y: +80%)
Market Cap 249.9 M P/E(ttm) 16.40
Enterprise Value 193.89 M P/B 3.70
RGEN- NAS (USA)
Repligen Corporation
  • Currently 1/5
Business Predictability Rank: 1-Star
Back Testing Results:
Average gain of all 1-Star stocks: 1.1% per year.
% of Stocks that are in still loss if held for 10yrs: 45%.
Read more:
What is Predictability Rank?
Performances of real portfolio
Top Ranked Predictable Companies
$7.92
Switch to:

GuruFocus Financial Strength Rank measures how strong a companyย’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry		 vs
history
Cash to Debt No Debt
RGEN's Cash to Debt is ranked higher than
83% of the 834 Companies
in the Global Biotechnology industry.

( Industry Median: 3.50 vs. RGEN: No Debt )
RGEN' s 10-Year Cash to Debt Range
Min: 143.42   Max: No Debt
Current: No Debt
Equity to Asset 0.928
RGEN's Equity to Asset is ranked higher than
96% of the 834 Companies
in the Global Biotechnology industry.

( Industry Median: 0.53 vs. RGEN: 0.928 )
RGEN' s 10-Year Equity to Asset Range
Min: 0.88   Max: 0.97
Current: 0.93
0.88
0.97
Interest Coverage 280.4
RGEN's Interest Coverage is ranked higher than
78% of the 834 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. RGEN: 280.4 )
RGEN' s 10-Year Interest Coverage Range
Min: 280   Max: No Debt
Current: 280.4
F-Score: 6
Z-Score: 14.97
M-Score: -2.84
GuruFocus Profitability Rank ranks how profitable a company is and how likely the companyย’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
ย•ย•3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rankย•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry		 vs
history
Operating margin (%) 20.40
RGEN's Operating margin (%) is ranked higher than
93% of the 834 Companies
in the Global Biotechnology industry.

( Industry Median: -4.90 vs. RGEN: 20.40 )
RGEN' s 10-Year Operating margin (%) Range
Min: -312.4   Max: 186
Current: 20.4
-312.4
186
Net-margin (%) 23.2
RGEN's Net-margin (%) is ranked higher than
94% of the 834 Companies
in the Global Biotechnology industry.

( Industry Median: -4.20 vs. RGEN: 23.2 )
RGEN' s 10-Year Net-margin (%) Range
Min: -224.9   Max: 192.3
Current: 23.2
-224.9
192.3
Revenue Growth (%) 22.1
RGEN's Revenue Growth (%) is ranked higher than
95% of the 834 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. RGEN: 22.1 )
RGEN' s 10-Year Revenue Growth (%) Range
Min: 3.4   Max: 26.4
Current: 22.1
3.4
26.4
EBITDA Growth (%) 35.5
RGEN's EBITDA Growth (%) is ranked higher than
98% of the 834 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. RGEN: 35.5 )
RGEN' s 10-Year EBITDA Growth (%) Range
Min: -57   Max: 36.8
Current: 35.5
-57
36.8
EPS Growth (%) 28.1
RGEN's EPS Growth (%) is ranked higher than
97% of the 834 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. RGEN: 28.1 )
RGEN' s 10-Year EPS Growth (%) Range
Min: -100   Max: 73.2
Current: 28.1
-100
73.2
ยป RGEN's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades
Q2 2012

RGEN Guru Trades in Q2 2012

Jim Simons 692,100 sh (+14.06%)
» More
Q3 2012

RGEN Guru Trades in Q3 2012

Jim Simons 651,100 sh (-5.92%)
» More
Q4 2012

RGEN Guru Trades in Q4 2012

Jim Simons 548,308 sh (-15.79%)
» More
Q1 2013

RGEN Guru Trades in Q1 2013

Jim Simons 426,302 sh (-22.25%)
» More
» Details

Insider Trades

Latest Guru Trades with RGEN



No Insider Trades Found!
ยป Financial Charts

Peter Lynch Chart

Ratios

vs
industry		 vs
history
P/E(ttm) 16.40
RGEN's P/E(ttm) is ranked higher than
84% of the 252 Companies
in the Global Biotechnology industry.

( Industry Median: 26.90 vs. RGEN: 16.40 )
RGEN' s 10-Year P/E(ttm) Range
Min: 3.18   Max: 534
Current: 16.4
3.18
534
P/B 3.70
RGEN's P/B is ranked higher than
68% of the 606 Companies
in the Global Biotechnology industry.

( Industry Median: 3.56 vs. RGEN: 3.70 )
RGEN' s 10-Year P/B Range
Min: 1.21   Max: 11.01
Current: 3.7
1.21
11.01
P/S 3.80
RGEN's P/S is ranked higher than
82% of the 677 Companies
in the Global Biotechnology industry.

( Industry Median: 7.38 vs. RGEN: 3.80 )
RGEN' s 10-Year P/S Range
Min: 2.99   Max: 97.79
Current: 3.8
2.99
97.79
PFCF 18.40
RGEN's PFCF is ranked higher than
76% of the 244 Companies
in the Global Biotechnology industry.

( Industry Median: 27.82 vs. RGEN: 18.40 )
RGEN' s 10-Year PFCF Range
Min: 3.18   Max: 379
Current: 18.4
3.18
379
EV-to-EBIT 15.2
RGEN's EV-to-EBIT is ranked higher than
80% of the 244 Companies
in the Global Biotechnology industry.

( Industry Median: 22.58 vs. RGEN: 15.2 )
RGEN' s 10-Year EV-to-EBIT Range
Min: 11.3   Max: 51.1
Current: 15.2
11.3
51.1
Shiller P/E 21
RGEN's Shiller P/E is ranked lower than
100% of the Companies
in the Global Biotechnology industry.

( Industry Median: vs. RGEN: 21 )
RGEN' s 10-Year Shiller P/E Range
Min: 11.21   Max: 62.73
Current: 21
11.21
62.73

Valuation & Return

vs
industry		 vs
history
Price/Net Cash 5.6
RGEN's Price/Net Cash is ranked higher than
64% of the 295 Companies
in the Global Biotechnology industry.

( Industry Median: 8.90 vs. RGEN: 5.6 )
RGEN' s 10-Year Price/Net Cash Range
Min: 2.6   Max: 9.3
Current: 5.6
2.6
9.3
Price/Net Current Asset Value 46.6
RGEN's Price/Net Current Asset Value is ranked higher than
50% of the 502 Companies
in the Global Biotechnology industry.

( Industry Median: 45.80 vs. RGEN: 46.6 )
RGEN' s 10-Year Price/Net Current Asset Value Range
Min: 22   Max: 87.5
Current: 46.6
22
87.5
Price/Tangible Book 3.8
RGEN's Price/Tangible Book is ranked higher than
67% of the 564 Companies
in the Global Biotechnology industry.

( Industry Median: 5.60 vs. RGEN: 3.8 )
RGEN' s 10-Year Price/Tangible Book Range
Min: 1.8   Max: 5.9
Current: 3.8
1.8
5.9
Price/DCF (Projected) 1.2
RGEN's Price/DCF (Projected) is ranked higher than
87% of the 127 Companies
in the Global Biotechnology industry.

( Industry Median: 2.20 vs. RGEN: 1.2 )
RGEN' s 10-Year Price/DCF (Projected) Range
Min: 0.8   Max: 1.4
Current: 1.2
0.8
1.4
Price/Median PS Value 0.5
RGEN's Price/Median PS Value is ranked higher than
92% of the 550 Companies
in the Global Biotechnology industry.

( Industry Median: 1.00 vs. RGEN: 0.5 )
RGEN' s 10-Year Price/Median PS Value Range
Min: 0.4   Max: 7.5
Current: 0.5
0.4
7.5
Earnings Yield (Greenblatt) 6.60
RGEN's Earnings Yield (Greenblatt) is ranked higher than
89% of the 834 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. RGEN: 6.60 )
RGEN' s 10-Year Earnings Yield (Greenblatt) Range
Min: 2   Max: 8.8
Current: 6.6
2
8.8
Forward Rate of Return (Yacktman) 2.83
RGEN's Forward Rate of Return (Yacktman) is ranked higher than
94% of the 834 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. RGEN: 2.83 )
RGEN' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 2.9   Max: 6.4
Current: 2.83
2.9
6.4

Business Description

Repligen Corporation was incorporated in May 1981, under the laws of the State of Delaware. The Company is a supplier of critical products used to manufacture biologic drugs. The Company manufactures Protein A for major life science companies under long term supply agreements and also sell products directly to end users for use in their manufacturing processes. The Company also applies its expertise in biologic product development to SecreFlo TM (RG1068), for which its first new drug application (NDA) has been submitted and accepted for priority review by the U.S. Food and Drug Administration (FDA) and for which it hassubmitted a marketing authorization application (MAA) to the European Medicines Agency (EMA). SecreFlo is a synthetic human hormone being developed by the Company as a novel imaging agent for the diagnosis of pancreatitis and potentially a variety of pancreatic diseases. The Company also has two early stage central nervous system (CNS) rare disease programs underway in Friedreich's ataxia and spinal muscular atrophy that are advancing into Phase 1 clinical trials. In addition, it has out-licensed certain intellectual property to Bristol-Myers Squibb Company (Bristol) from which it receives royalties on their net sales in the United States of their product Orencia. The Company currently sells various commercial bioprocessing products based on Protein A and IFG-1 growth factors, as well as a line of pre-packed chromatography columns, which are used in the production of monoclonal antibodies and other biopharmaceutical products. Repligen is a manufacturer of a number of bioprocessing products including multiple products based on Protein A, growth factors used in fermentation and a line of pre-packed chromatography columns. The Company's bioprocessing products are used in the production of biologic drugs which include a wide range of recombinant therapeutic proteins, monoclonal antibodies and vaccines. Demand for its bioprocessing products has grown in concert with the expanding markets for biologics, particularly monoclonal antibodies. Monoclonal antibodies are highly valuable therapeutic agents, examples of which include some of the best-selling drugs in the world such as Enbrel and Remicade for rheumatoid arthritis and other inflammatory disorders, and Rituxan for Non-Hodgkin's Lymphoma. There are more than 50 approved monoclonal antibody products and 200 product candidates currently in clinical development, most of which are manufactured using Protein A. The Company currently has three active development stage programs underway including its diagnostic imaging program and two early stage central nervous system (CNS) rare disease programs. SecreFlo (RG0168, synthetic human secretin) is being developed to be used in combination with magnetic resonance imaging (MRI) to improve the detection of pancreatic abnormalities in patients with pancreatitis. The development of drug candidates is subject to regulation in the Unit
Company Website
SEC Reports
Industry: Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG
Traded in other countries:RGN.Germany
ยป More Articles for RGEN

Headlines

Articles On GuruFocus.com
Repligen Corp. Reports Operating Results (10-Q) Feb 09 2011 
Repligen Corp. Reports Operating Results (10-Q) Nov 02 2010 
Repligen Corp. Reports Operating Results (10-Q) Aug 05 2010 
Repligen Corp. Reports Operating Results (10-Q) Feb 04 2010 
Repligen Corp. Reports Operating Results (10-Q) Nov 05 2009 
Repligen Reports First Quarter Fiscal Year 2010 Financial Results Aug 06 2009 
Repligen Corp. Reports Operating Results (10-Q) Feb 06 2009 

Personalized Checklist





Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK